m7-FLIPI 对一线利妥昔单抗无化疗方案滤泡性淋巴瘤患者无预后价值
本研究基于北欧淋巴瘤组两项随机试验,评估 m7-FLIPI 在 95 例接受一线利妥昔单抗无化疗方案的滤泡性淋巴瘤患者中的预后价值。结论提示 m7-FLIPI 的预后价值可能取决于治疗 regimen。
要点
- m7-FLIPI 不能预测一线利妥昔单抗无化疗患者的 TTF 或 OS。
- EZH2 突变与较长 TTF 相关,EP300 突变与较短 TTF 相关。
- m7-FLIPI 的预后价值可能依赖于治疗 regimen。
核心结论
- m7-FLIPI 的预后价值似乎取决于治疗 regimen,在利妥昔单抗无化疗方案中未能分层 TTF 或 OS。
研究设计与样本
- 北欧淋巴瘤组两项随机临床试验,纳入接受单药利妥昔单抗或利妥昔单抗联合干扰素-α2a 的惰性淋巴瘤患者,其中 95 例滤泡性淋巴瘤患者有足够新鲜冷冻诊断材料用于测序。
关键数值与推荐
- m7-FLIPI 整合体能状态、FLIPI 评分及 EZH2、ARID1A、MEF2B、EP300、FOXO1、CREBBP、CARD11 七个基因的突变状态。
- TTF 定义为试验治疗开始至新治疗启动或死亡的时间间隔。
临床怎么用
- 在采用一线利妥昔单抗无化疗方案的滤泡性淋巴瘤患者中,不应依据 m7-FLIPI 进行风险分层。
- EZH2 和 EP300 突变状态可能与 TTF 相关,但需进一步验证。
局限性
- 样本量有限(95 例滤泡性淋巴瘤患者)。
- 测序仅纳入七个基因的靶向 panel。
- 结果基于特定无化疗方案,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The clinical course of follicular lymphoma (FL) is highly variable. Recently the m7-FL international prognostic index (FLIPI) integrating performance status, FLIPI score and the mutational status of seven genes, was shown to stratify patients into "low-risk" and "high-risk" with respect to 5-year failure-free survival after first-line immunochemotherapy. Our aim was to evaluate the model after rituximab without chemotherapy. The Nordic Lymphoma Group performed two randomized clinical trials on indolent lymphoma patients receiving single rituximab and rituximab with interferon-α2a. In total, 95 FL patients had sufficient fresh-frozen diagnostic material for sequencing. A targeted panel for the genes EZH2, ARID1A, MEF2B, EP300, FOXO1, CREBBP and CARD11 was utilized for m7-FLIPI score calculation. With a median follow-up of 10·6 years, 76% of patients were alive. No difference in time to treatment failure (TTF), defined as the interval between start of trial therapy and initiation of new therapy or death, nor overall survival (OS) was found between the m7-FLIPI risk groups (log-rank P = 0·94 and 0·99, respectively). EZH2 mutations were associated with longer TTF (log-rank P = 0·04) and in EP300 mutations were associated with shorter TTF (log-rank P = 0·01). We conclude that the prognostic value of the m7-FLIPI clinicogenetic model seems dependent on therapeutic regimen.
引用
- Lockmer S, Ren W, Brodtkorb M, et al. M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy. Br J Haematol. 2019. PMID: 31423576. doi:10.1111/bjh.16159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。